Nearly two years after launching, a startup focused on still-experimental drugs using "transfer RNA" has raised $109 million in venture capital.
Alltrna, which is backed by Flagship Pioneering, did not name any other investors as part of its Series B investment round, saying only that "a number of top-tier investors" also participated in the financing.
The startup said it has hit a handful of milestones since it launched in November 2021. Alltrna has grown from 30 employees to 65; hired a permanent…
